메뉴 건너뛰기




Volumn 17, Issue 3-4, 2010, Pages 161-169

Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies

Author keywords

Capecitabine; Diarrhea; Herbal medicines; PHY906

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; EMOLLIENT AGENT; PHY 906; PLANT EXTRACT; PYRIDOXINE; UNCLASSIFIED DRUG;

EID: 75249102511     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2009.12.016     Document Type: Article
Times cited : (81)

References (23)
  • 1
    • 40649090312 scopus 로고    scopus 로고
    • Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer
    • Boeck S., Wilkowski R., Bruns C.J., et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 73 3-4 (2007) 221-227
    • (2007) Oncology , vol.73 , Issue.3-4 , pp. 221-227
    • Boeck, S.1    Wilkowski, R.2    Bruns, C.J.3
  • 2
    • 8244254377 scopus 로고    scopus 로고
    • Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
    • Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15 6 (1997) 2403-2413
    • (1997) J. Clin. Oncol. , vol.15 , Issue.6 , pp. 2403-2413
    • Burris III, H.A.1    Moore, M.J.2    Andersen, J.3
  • 3
    • 0036137690 scopus 로고    scopus 로고
    • Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer
    • Cartwright T.H., Cohn A., Varkey J.A., et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J. Clin. Oncol. 20 1 (2002) 160-164
    • (2002) J. Clin. Oncol. , vol.20 , Issue.1 , pp. 160-164
    • Cartwright, T.H.1    Cohn, A.2    Varkey, J.A.3
  • 4
    • 33646529151 scopus 로고    scopus 로고
    • Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden
    • Davison S.N., Jhangri G.S., and Johnson J.A. Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int. 69 9 (2006) 1621-1625
    • (2006) Kidney Int. , vol.69 , Issue.9 , pp. 1621-1625
    • Davison, S.N.1    Jhangri, G.S.2    Johnson, J.A.3
  • 5
    • 0037302385 scopus 로고    scopus 로고
    • Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer
    • Farrell M.P., and Kummar S. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer. Clin. Colorectal Cancer 2 4 (2003) 253-256
    • (2003) Clin. Colorectal Cancer , vol.2 , Issue.4 , pp. 253-256
    • Farrell, M.P.1    Kummar, S.2
  • 8
    • 0012734882 scopus 로고    scopus 로고
    • Chinese medicine formulation, PHY-906, can enhance the therapeutic Index of CPT-11 and other anticancer drugs against cancer in mice
    • Liu S.-H., Jiang Z., and Cheng Y.-C.A. Chinese medicine formulation, PHY-906, can enhance the therapeutic Index of CPT-11 and other anticancer drugs against cancer in mice. Proc. Am. Assoc. Cancer Res. 42 85 (2001) 458
    • (2001) Proc. Am. Assoc. Cancer Res. , vol.42 , Issue.85 , pp. 458
    • Liu, S.-H.1    Jiang, Z.2    Cheng, Y.-C.A.3
  • 9
    • 71949100830 scopus 로고    scopus 로고
    • PHY906, a Chinese herbal formulation enhances the therapeutic effect of cancer chemotherapy in human colorectal and liver cancer
    • Liu S.-H., Jiang Z., Gao W., et al., PHY906, a Chinese herbal formulation enhances the therapeutic effect of cancer chemotherapy in human colorectal and liver cancer. In: Proc. Am. Soc. Clin. Oncol. 2003;Abstr #864.
    • Proc. Am. Soc. Clin. Oncol. 2003;Abstr , Issue.864
    • Liu, S.-H.1    Jiang, Z.2    Gao, W.3
  • 11
    • 3042524200 scopus 로고    scopus 로고
    • Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma
    • Milella M., Gelibter A., Di Cosimo S., et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 101 1 (2004) 133-138
    • (2004) Cancer , vol.101 , Issue.1 , pp. 133-138
    • Milella, M.1    Gelibter, A.2    Di Cosimo, S.3
  • 12
    • 33745787917 scopus 로고    scopus 로고
    • Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a Phase II trial.
    • Mitry E., Ducreux M., Ould-Kaci M., et al. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a Phase II trial. Gastroenterol. Clin. Biol. 30 3 (2006) 357-363
    • (2006) Gastroenterol. Clin. Biol. , vol.30 , Issue.3 , pp. 357-363
    • Mitry, E.1    Ducreux, M.2    Ould-Kaci, M.3
  • 13
    • 31044440384 scopus 로고    scopus 로고
    • Edmonton symptom assessment scale: Italian validation in two palliative care settings
    • Moro C., Brunelli C., Miccinesi G., et al. Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer 14 1 (2006) 30-37
    • (2006) Support Care Cancer , vol.14 , Issue.1 , pp. 30-37
    • Moro, C.1    Brunelli, C.2    Miccinesi, G.3
  • 14
    • 33646783722 scopus 로고    scopus 로고
    • Common Terminology Criteria for Adverse Events v3.0 (CTCAE). (Publish date
    • National Cancer Institute U.S. National Institute of Health, August 9
    • National Cancer Institute U.S. National Institute of Health. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). (Publish date August 9, 2006).
    • (2006)
  • 15
    • 58749093918 scopus 로고    scopus 로고
    • CONKO-1: Final results of the randomized, prospective, multicenter Phase III trial of adjuvant chemotherapy with gemcitabine versus observation with resected pancreatic cancer
    • (May 20 suppl, LBA4504)
    • Neuhaus P., Riess H., Post S., et al. CONKO-1: Final results of the randomized, prospective, multicenter Phase III trial of adjuvant chemotherapy with gemcitabine versus observation with resected pancreatic cancer. JCO 26 (2008) (May 20 suppl, LBA4504)
    • (2008) JCO , vol.26
    • Neuhaus, P.1    Riess, H.2    Post, S.3
  • 16
    • 75249086214 scopus 로고    scopus 로고
    • Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma
    • Saif M.W., Liu S., Elfiky A., Jiang Z., and Cheng Y. Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma. J. Clin. Oncol. 25 18S (2007) 15116
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18 S , pp. 15116
    • Saif, M.W.1    Liu, S.2    Elfiky, A.3    Jiang, Z.4    Cheng, Y.5
  • 17
    • 48949099568 scopus 로고    scopus 로고
    • Is there a role for herbal medicine in the treatment of pancreatic cancer? Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30-June 3, 2008
    • Saif M.W. Is there a role for herbal medicine in the treatment of pancreatic cancer? Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30-June 3, 2008. JOP 9 4 (2008) 403-407
    • (2008) JOP , vol.9 , Issue.4 , pp. 403-407
    • Saif, M.W.1
  • 18
    • 0037837645 scopus 로고    scopus 로고
    • Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer
    • Scheithauer W., Kornek G.V., Raderer M., et al. Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 21 7 (2003) 1307-1312
    • (2003) J. Clin. Oncol. , vol.21 , Issue.7 , pp. 1307-1312
    • Scheithauer, W.1    Kornek, G.V.2    Raderer, M.3
  • 19
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 3 (2000) 205-216
    • (2000) J. Natl. Cancer Inst. , vol.92 , Issue.3 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 20
    • 42949171085 scopus 로고    scopus 로고
    • Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer
    • Traina T.A., Theodoulou M., Feigin K., et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J. Clin. Oncol. 26 11 (2008) 1797-1802
    • (2008) J. Clin. Oncol. , vol.26 , Issue.11 , pp. 1797-1802
    • Traina, T.A.1    Theodoulou, M.2    Feigin, K.3
  • 21
    • 22144433634 scopus 로고    scopus 로고
    • Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a Phase II study
    • Tsavaris N., Kosmas C., Skopelitis H., et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a Phase II study. Invest. New Drugs 23 4 (2005) 369-375
    • (2005) Invest. New Drugs , vol.23 , Issue.4 , pp. 369-375
    • Tsavaris, N.1    Kosmas, C.2    Skopelitis, H.3
  • 22
    • 33646531836 scopus 로고    scopus 로고
    • The Edmonton Symptom Assessment System as a screening tool for depression and anxiety
    • Vignaroli E., Pace E.A., Willey J., Palmer J.L., Zhang T., and Bruera E. The Edmonton Symptom Assessment System as a screening tool for depression and anxiety. J. Palliat. Med. 9 2 (2006) 296-303
    • (2006) J. Palliat. Med. , vol.9 , Issue.2 , pp. 296-303
    • Vignaroli, E.1    Pace, E.A.2    Willey, J.3    Palmer, J.L.4    Zhang, T.5    Bruera, E.6
  • 23
    • 75249091102 scopus 로고    scopus 로고
    • Phase I/II study of capecitabine and PHY906 in hepatocellular carcinoma
    • (May 20 suppl; abstr 4610)
    • Yen Y., So S., Rose M., et al. Phase I/II study of capecitabine and PHY906 in hepatocellular carcinoma. J. Clin. Oncol. 26 (2008) (May 20 suppl; abstr 4610)
    • (2008) J. Clin. Oncol. , vol.26
    • Yen, Y.1    So, S.2    Rose, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.